All News
Don't Blame the Weather in Sjogren's
Seasonal variations in symptoms -- commonly reported by patients with rheumatic diseases -- were not observed in a large cohort of patients with primary Sjogren's syndrome, French investigators found.
Read Article
Folate Levels Protect from CV Mortality in RA
In a study of rheumatoid arthritis (RA) patients, JAMA reports that serum folate level of greater than 4.3 ng/mL was associated with lower CV mortality risk.
Read Article
Fatigue Looms Large in Lupus
Fatigue is an important component of the disease experience in systemic lupus erythematosus (SLE), and can have a profound impact on patients' perception of well-being, Italian researchers reported.
Read Article
Why You Should Come to RheumNow Live March 13th
RheumNow Live kicks off its second annual meeting - a little, big meeting in Fort Worth - in just 2 weeks and I think you should be there.
Read Article
ACR Releases Reproductive Health Guidelines for Rheumatic Diseases
Today, the American College of Rheumatology (ACR) published the 2020 Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.
Read Article
Hyperuricemia Predisposes to Coronary Artery Disease in Men
There are numerous associations between hyperuricemia and cardiovascular disease (CVD). An analysis of the Swedish SCAPIS Pilot study shows that higher levels of serum urate (SU) are associated with an increase in coronary artery calcification score in men but not in women. SU is not associated with common carotid intima-media thickness and carotid plaque scores in either men or women.
Read Article
No Cancer Increase in Psoriatic Arthritis or with Biologics in Psoriasis
JAMA Dermatology reports that psoriasis is associated with a slightly increased risk of cancer, particularly keratinocyte cancer and lymphomas.
Read Article
Tofacitinib Effective in Refractory Still's Disease
Fourteen cases reported from mainland China suggest that tofacitinib (TOFA) may be effective in patients with refractory adult-onset Still’s disease (AOSD), further adding to a growing list of potential use of JAK inhibition in managing inflammatory, and now autoinflammatory, disease.
Read Article
Seronegativity on the Rise in RA
Although the overall incidence rates of rheumatoid arthritis (RA) have remained stable over recent decades, there has been a significant increase in seronegative cases, a retrospective study showed.
Read Article
Adverse Effects of Low-Dose Methotrexate from the CIRT Trial
Low-dose methotrexate (LD-MTX) was studied in high risk cardiac patients in the cardiac intervention trial (CIRT), but was prematurely ended for not showing a change in cardiovascular event rates. Nonetheless this trial studied the safety and adverse event rates of LD-MTX and those results are reported in the current issue of Annals of Internal Medicine.
RheumNow Podcast - RWCS Quick Hits (2.14.20)
Dr. Jack Cush reviews the highlights from the 2020 RWCS meeting in Maui, Hawaii.
Read Article
PEXIVAS - Plasma Exhange Fails to Boost Outcomes in Severe AAV
The PEXIVAS study showed that plasma exchange did not reduce the incidence of death or ESKD in patients with severe ANCA–associated vasculitis.
Read Article
Shingles Vaccine Lowers Risk of CVA
Shingles infection has been historically linked to an increased risk of stroke. A new study found that Zoster Vaccine Live, one type of shingles vaccination, may prevent stroke in some older adults.
Read Article
Alcohols Net Zero Effect in Rheumatoid Arthritis
A report from The National Databank for Rheumatic Disease addressed the impact of alcohol on disease activity and mortality in rheumatoid arthritis (RA) and found that alcohol use was not associated with changes in disease activity or mortality, after addressing confounders.
Read Article
Overmedication of America
Recent research from the Lown Institute reports that 750 older Americans are hospitalized daily because of serious side effects from and the core problem is that of polypharmacy, especially in the elderly.
Read Article
DMARD Inertia by Registry Rheumatologists
A registry study of metric use (primarily RAPID3 and CDAI) in the treatment of rheumatoid arthritis (RA) patients shows that, even in the face of moderate or high disease activity, treatment changes by rheumatologists were relatively low (35.6–54.6%).
Read Article
Upadacitinib Effective in Phase 3 Psoriatic Arthritis Study
Abbvie has announced top line results of their SELECT-PSA trial of upadacitinib (UPA), wherein both the 15 and 30 mg doses met the primary endpoint of ACR20 response at week 12 and demonstrated radiographic inhibition at week 24.
Read Article
Which Biologics are Best in Psoriasis
A metanalysis of phase II, III and IV trials in moderate to severe plaque psoriasis suggests comparative efficacy biologic treatments, but that that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were shown to have the past skin (PASI) response rates.
Read Article
Limited Advantage to Very Early vs. Delayed Etanercept in RA
The VEDERA study sought to confirm whether the very early introduction of first-line etanercept+methotrexate (ETN+MTX) was superior to treat-to-target MTX (MTX-TT) in patients with early RA.
Read Article
RheumNow Podcast- 2019 EULAR RA Guidelines (1.31.20)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
